@article{oai:repo.qst.go.jp:00047005,
 author = {Hashimoto, Hiroki and Kawamura, Kazunori and Igarashi, Nobuyuki and Takei, Makoto and Fujishiro, Tomoya and Aihara, Yoshiharu and Shiomi, Satoshi and Muto, Masatoshi and Ito, Takehito and Furutsuka, Kenji and Yamasaki, Tomoteru and Yui, Joji and Xie, Lin and Ono, Maiko and Hatori, Akiko and Nemoto, Kazuyoshi and Suhara, Tetsuya and Higuchi, Makoto and Zhang, Ming-Rong and 橋本 裕輝 and 河村 和紀 and 五十嵐 延行 and 武井 誠 and 藤代 智也 and 相原 由治 and 潮見 聡 and 武藤 正敏 and 伊藤 岳人 and 古塚 賢士 and 山崎 友照 and 由井 譲二 and 謝 琳 and 小野 麻衣子 and 羽鳥 晶子 and 根本 和義 and 須原 哲也 and 樋口 真人 and 張 明栄},
 issue = {9},
 journal = {Journal of nuclear medicine},
 month = {Jun},
 note = {2-((1E,3E)-4-(6-((11)C-methylamino)pyridin-3-yl)buta-1,3-dienyl)benzo[d]thiazol-6-ol ((11)C-PBB3) is a clinically useful PET probe that we developed for in vivo imaging of tau pathology in the human brain. To ensure the availability of this probe among multiple PET facilities, in the present study we established protocols for the radiosynthesis and quality control of (11)C-PBB3 and for the characterization of its photoisomerization, biodistribution, and metabolism.},
 pages = {1532--1538},
 title = {Radiosynthesis, Photoisomerization, Biodistribution, and Metabolite Analysis of 11C-PBB3 as a Clinically Useful PET Probe for Imaging of Tau Pathology.},
 volume = {55},
 year = {2014}
}